dual Abl/Src inhibitors (OriBase Pharma)

N/A

Report date: 2025/03/19 08:56:51
NME

Base Information

Drug Namedual Abl/Src inhibitors (OriBase Pharma)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsTyrosine-protein kinase SRC inhibitors
TargetsTyrosine-protein kinase SRCBcr-Abl tyrosine kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOriBase Pharma
China Registration ClassN/A

Develop Information

Active CompaniesOriBase Pharma
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A